Pages that link to "Q42972374"
Jump to navigation
Jump to search
The following pages link to Qing Ma (Q42972374):
Displaying 50 items.
- Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals (Q28069383) (← links)
- Studies on the effect of calcium in interactions between heparin and heparin cofactor II using surface plasmon resonance (Q28271545) (← links)
- Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection (Q28548638) (← links)
- Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies (Q33343793) (← links)
- Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. (Q34081535) (← links)
- Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. (Q34495619) (← links)
- Clinical application of the paraspinal erector approach for spinal canal decompression in upper lumber burst fractures (Q34558478) (← links)
- Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders. (Q35061983) (← links)
- Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice (Q35213469) (← links)
- Interactions Between Buprenorphine and the Protease Inhibitors Darunavir-Ritonavir and Fosamprenavir-Ritonavir (Q35672530) (← links)
- Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. (Q35738878) (← links)
- Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile. (Q35743488) (← links)
- Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults (Q35829744) (← links)
- The impact of herbal drug use on adverse drug reaction profiles of patients on antiretroviral therapy in zimbabwe (Q35855545) (← links)
- Global HIV/AIDS Clinical and Translational Pharmacology (Q36125023) (← links)
- Recent advances in management of the HIV/HCV coinfected patient (Q36575497) (← links)
- Critical pathways: the role of pharmacy today and tomorrow. (Q36582696) (← links)
- Drug interactions between proton pump inhibitors and antiretroviral drugs. (Q36788409) (← links)
- Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir (Q36826482) (← links)
- Advances in pharmacogenomics of antiretrovirals: an update. (Q36966025) (← links)
- Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir. (Q37045335) (← links)
- Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients. (Q37140177) (← links)
- Research in women and special populations (Q37254474) (← links)
- Host proteome research in HIV infection. (Q37318371) (← links)
- Pharmacogenomics of CYP3A: considerations for HIV treatment (Q37419542) (← links)
- Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. (Q37528417) (← links)
- Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy (Q37688260) (← links)
- Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism (Q37699049) (← links)
- Therapeutic drug monitoring in highly active antiretroviral therapy. (Q37720765) (← links)
- Pharmacologic approaches to the treatment of Huntington's disease (Q37945478) (← links)
- Aspirin responsiveness changes in obese patients following bariatric surgery (Q38818898) (← links)
- Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans (Q38868951) (← links)
- Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals (Q40100880) (← links)
- Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus. (Q40118824) (← links)
- Comparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients. (Q40131806) (← links)
- Disulfiram metabolite S-methyl-N,N-diethylthiocarbamate quantitation in human plasma with reverse phase ultra performance liquid chromatography and mass spectrometry. (Q42130690) (← links)
- Single-tablet, once-daily treatment regimens for HIV. (Q42222138) (← links)
- CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients (Q42972297) (← links)
- Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist (Q43588770) (← links)
- Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use. (Q44366007) (← links)
- Influence of different anticoagulant agents on fibrinopeptide a generation (Q44678428) (← links)
- Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications (Q45330127) (← links)
- Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia (Q45855929) (← links)
- Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population (Q46506742) (← links)
- Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir (Q46866962) (← links)
- Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients (Q46880890) (← links)
- Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. (Q46955645) (← links)
- Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan (Q47428416) (← links)
- The blood-brain barrier accessibility of a heparin-derived oligosaccharides C3. (Q48581408) (← links)
- Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients (Q51553332) (← links)